Alumis
Kolbot has extensive work experience in the pharmaceutical industry, with a strong background in technical operations and chemical development. They have held senior-level positions at various companies, including Alumis, Rain Therapeutics, and Principia Biopharma. Kolbot's roles have included Vice President, Chemical Development, Senior Director, and SVP Tech Ops. They have also gained experience in research and academia, working as a Post Doctoral Researcher at the University of CA, Berkeley and a Doctoral Candidate at the University of CA, Davis. Kolbot's career began as a Research Associate at NPS Pharmaceuticals, Inc.
Kolbot obtained a Ph.D. in Chemistry from the University of California, Davis, between 1998 and 2003. Prior to that, they earned a Bachelor of Science in Chemistry from UC Santa Barbara during the period of 1990-1994.
Alumis
2 followers
At Alumis, our goal is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. We recognize that patients living with immune-mediated diseases need alternatives to currently available therapies. Despite recent advances and innovations in the treatment of immune-mediated diseases, many patients continue to suffer, cycling through currently approved therapies while looking for a solution that alleviates the debilitating impact of their disease without life-limiting side effects. Addressing the needs of these patients is why we exist. We are pioneering a precision approach that leverages insights we derive from powerful data analytics to select the right target, right molecule, right indication, right patient, and right endpoint resulting in optimized outcomes for patients. We believe that combining our insights with an integrated approach to drug development will produce the next generation of treatments to address immune dysfunction. Incubated by Foresite Labs, Alumis is led by a team of deeply experienced professionals who are devoted to transforming the lives of patients with immune-mediated diseases by developing a pipeline of transformative therapies.